Optic Neuropathy
VIDEO: Optogenetic therapy shows vision improvements, safety at 12 months
SEATTLE — In this Healio Video Perspective from the ARVO meeting, Allen C. Ho, MD, FASRS, discusses 12-month data on MCO-010 optogenetic therapy for patients with retinitis pigmentosa.
Woman presents with unilateral, painless vision loss
A 57-year-old woman was transferred to Lahey Hospital and Medical Center emergency department from a community hospital for an ophthalmology evaluation due to acute, painless vision loss in the left eye upon wakening that morning.
Lumevoq shows sustained efficacy, safety 4 years after one-time LHON treatment
Lumevoq demonstrated sustained efficacy and a positive safety profile at 4 years after a one-time injection of the gene therapy in patients with Leber hereditary optic neuropathy, according to a press release from GenSight Biologics.
More focus needed on optic nerve to diagnose severe glaucoma
WAILEA, Hawaii — Clinicians should look more closely at the optic nerve to diagnose cases of severe glaucoma, according to a speaker at Hawaiian Eye 2024.
Lumevoq demonstrates sustained improvement of BCVA up to 5 years in LHON
BOSTON — Results from the long-term RESTORE study show patients with Leber hereditary optic neuropathy with ND4 mutation who were treated with Lumevoq had sustained improvement of best-corrected visual acuity in both eyes.
Man referred for acute unilateral vision loss upon waking
A 55-year-old man at Tufts Medical Center for hypovolemic shock due to a gastrointestinal hemorrhage was referred to the inpatient ophthalmology consult service for left eye acute painless inferior visual field loss upon waking.
Real-world data show positive results for Tepezza in dysthyroid optic neuropathy
An analysis of real-world data showed that Tepezza helped improve visual acuity in patients with dysthyroid optic neuropathy, according to a press release.
Lumevoq gene therapy shows sustained efficacy, safety at 3 years in phase 3 LHON trial
A phase 3 clinical trial demonstrated positive 3-year results for bilateral intravitreal injection of Lumevoq gene therapy, with statistically significant visual acuity improvements from baseline in both treated eyes.
Boy presents with decreased vision after accidental eye trauma
A 7-year-old boy was referred to the neuro-ophthalmology clinic at the New England Eye Center for evaluation of decreased vision in the right eye.
Woman presents with progressive left eye proptosis, upper lid edema
A 41-year-old woman was referred to the neuro-ophthalmology service at the New England Eye Center for left-sided proptosis, left upper lid edema and progressively worsening vision in the left eye for about 5 months.